Skip to main content
Erschienen in: Tumor Biology 4/2013

01.08.2013 | Research Article

RETRACTED ARTICLE: CYP2D6 T188C variant is associated with lung cancer risk in the Chinese population

verfasst von: Yan Huang, Xin Liu, Xin Kuang, Duanfang Liao

Erschienen in: Tumor Biology | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

The CYP2D6 gene has been suggested to play an important role in the pathogenesis of lung cancer. However, the results have been inconsistent. In this study, we performed a meta-analysis to clarify the association of CYP2D6 T188C variant with lung cancer. Published literature from PubMed, Embase, Chinese National Knowledge Infrastructure and Wanfang data were retrieved. Pooled odds ratio (OR) with 95 % confidence interval (CI) was calculated using fixed- or random-effects model. A total of nine studies (1,516 lung cancer cases and 1,950 controls) for CYP2D6 T188C variant were included in the meta-analysis. The meta-analysis indicated that compared with CYP2D6 TT genotype, non-TT genotype (CC or CT) was significantly associated with lung cancer in the Chinese (OR = 1.61, 95 % CI = 1.38–1.87, p < 0.001), with no evidence of between-study heterogeneity (I 2 = 0.0 %, p = 0.991). The sensitivity analysis indicated that the association was stable and no publication bias was detected. The present meta-analysis supported the positive association of CYP2D6 T188C variant with lung cancer in the Chinese. Further large-scale studies with the consideration for gene–gene/gene–environment interactions should be conducted to investigate the association.
Literatur
1.
Zurück zum Zitat van Meerbeeck JP, Fennell DA, De Ruysscher DK. Small-cell lung cancer. Lancet. 2011;378:1741–55.CrossRefPubMed van Meerbeeck JP, Fennell DA, De Ruysscher DK. Small-cell lung cancer. Lancet. 2011;378:1741–55.CrossRefPubMed
2.
Zurück zum Zitat Piskac-Collier AL, Monroy C, Lopez MS, Cortes A, Etzel CJ, Greisinger AJ, et al. Variants in folate pathway genes as modulators of genetic instability and lung cancer risk. Genes Chromosomes Cancer. 2011;50:1–12.CrossRefPubMed Piskac-Collier AL, Monroy C, Lopez MS, Cortes A, Etzel CJ, Greisinger AJ, et al. Variants in folate pathway genes as modulators of genetic instability and lung cancer risk. Genes Chromosomes Cancer. 2011;50:1–12.CrossRefPubMed
3.
Zurück zum Zitat Daly AK, Cholerton S, Gregory W, Idle JR. Metabolic polymorphisms. Pharmacol Ther. 1993;57:129–60.CrossRefPubMed Daly AK, Cholerton S, Gregory W, Idle JR. Metabolic polymorphisms. Pharmacol Ther. 1993;57:129–60.CrossRefPubMed
4.
Zurück zum Zitat Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics. 2002;3:229–43.CrossRefPubMed Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics. 2002;3:229–43.CrossRefPubMed
5.
Zurück zum Zitat Gao Y, Zhang Q. Polymorphisms of the GSTM1 and CYP2D6 genes associated with susceptibility to lung cancer in Chinese. Mutat Res. 1999;444:441–9.CrossRefPubMed Gao Y, Zhang Q. Polymorphisms of the GSTM1 and CYP2D6 genes associated with susceptibility to lung cancer in Chinese. Mutat Res. 1999;444:441–9.CrossRefPubMed
6.
Zurück zum Zitat Gu Y, Zhang S, Lai B, Wang H, Zhan X. Relationship between genetic polymorphism of metabolizing enzymes and lung cancer susceptibility. Chin J Lung Cancer. 2004;7:112–7. Chinese. Gu Y, Zhang S, Lai B, Wang H, Zhan X. Relationship between genetic polymorphism of metabolizing enzymes and lung cancer susceptibility. Chin J Lung Cancer. 2004;7:112–7. Chinese.
7.
Zurück zum Zitat Li WY, Lai BT, Zhan XP. The relationship between genetic polymorphism of metabolizing enzymes and the genetic susceptibility to lung cancer. Chin J Epidemiol. 2004;25:1042–5. Chinese. Li WY, Lai BT, Zhan XP. The relationship between genetic polymorphism of metabolizing enzymes and the genetic susceptibility to lung cancer. Chin J Epidemiol. 2004;25:1042–5. Chinese.
8.
Zurück zum Zitat Guo Z, Zhou Q, Zhu W, Li D, Yuan T, Wang Y, et al. A case–control study on the association between genetic polymorphisms of metabolizing enzymes CYP2D6 and susceptibility to lung cancer. Chin J Lung Cancer. 2005;8:89–94. Chinese. Guo Z, Zhou Q, Zhu W, Li D, Yuan T, Wang Y, et al. A case–control study on the association between genetic polymorphisms of metabolizing enzymes CYP2D6 and susceptibility to lung cancer. Chin J Lung Cancer. 2005;8:89–94. Chinese.
9.
Zurück zum Zitat Liang GY. Studies on susceptibility genes of lung cancer in Chinese Han population and rapid detection techniques of single nucleotide polymorphisms. Doctoral Dissertation of Southeast University, 2005; 1–108. Chinese. Liang GY. Studies on susceptibility genes of lung cancer in Chinese Han population and rapid detection techniques of single nucleotide polymorphisms. Doctoral Dissertation of Southeast University, 2005; 1–108. Chinese.
10.
Zurück zum Zitat Gu YF, Zhang ZD, Zhang SC, Zheng SH, Jia HY, Gu SX. Combined effects of genetic polymorphisms in cytochrome P450s and GSTM1 on lung cancer susceptibility. Chin Med J. 2007;87:3064–8. Chinese. Gu YF, Zhang ZD, Zhang SC, Zheng SH, Jia HY, Gu SX. Combined effects of genetic polymorphisms in cytochrome P450s and GSTM1 on lung cancer susceptibility. Chin Med J. 2007;87:3064–8. Chinese.
11.
Zurück zum Zitat Yan Z, Wu YM, Wu YJ. CYP2D6*10 polymorphisms and lung cancer susceptibility. Acta Acad Med Sin. 2008;30:564–8. Chinese. Yan Z, Wu YM, Wu YJ. CYP2D6*10 polymorphisms and lung cancer susceptibility. Acta Acad Med Sin. 2008;30:564–8. Chinese.
12.
Zurück zum Zitat Zhang JJ. Single nucleotide polymorphisms of CYP2D6 gene G4268C, C188T and ERCC1 gene C8092A and their genetic susceptibility to lung cancer. Master's thesis of China Medical University, 2010; 1–37. Zhang JJ. Single nucleotide polymorphisms of CYP2D6 gene G4268C, C188T and ERCC1 gene C8092A and their genetic susceptibility to lung cancer. Master's thesis of China Medical University, 2010; 1–37.
13.
Zurück zum Zitat Zhou JL, Yao ZJ, Zeng ZP, Zhao XR, Xu Y, Cai XL, et al. Case–control study for the relationship of CYP1A1 and CYP2D6 polymorphisms with the genetic susceptibility to lung cancer. Acad J Guangdong Coll Pharm. 2011;27:528–31. Chinese. Zhou JL, Yao ZJ, Zeng ZP, Zhao XR, Xu Y, Cai XL, et al. Case–control study for the relationship of CYP1A1 and CYP2D6 polymorphisms with the genetic susceptibility to lung cancer. Acad J Guangdong Coll Pharm. 2011;27:528–31. Chinese.
14.
Zurück zum Zitat DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.CrossRefPubMed DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.CrossRefPubMed
15.
Zurück zum Zitat Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed
16.
Zurück zum Zitat Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.CrossRefPubMed Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.CrossRefPubMed
18.
Zurück zum Zitat Christensen PM, Gøtzsche PC, Brøsen K. The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: a meta-analysis. Eur J Clin Pharmacol. 1997;51:389–93.CrossRefPubMed Christensen PM, Gøtzsche PC, Brøsen K. The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: a meta-analysis. Eur J Clin Pharmacol. 1997;51:389–93.CrossRefPubMed
19.
Zurück zum Zitat Zhou LP, Luan H, Dong XH, Jin GJ, Man DL, Shang H. Genetic variants of CYP2D6 gene and cancer risk: a HuGE systematic review and meta-analysis. Asian Pac J Cancer Prev. 2012;13:3165–72.CrossRefPubMed Zhou LP, Luan H, Dong XH, Jin GJ, Man DL, Shang H. Genetic variants of CYP2D6 gene and cancer risk: a HuGE systematic review and meta-analysis. Asian Pac J Cancer Prev. 2012;13:3165–72.CrossRefPubMed
Metadaten
Titel
RETRACTED ARTICLE: CYP2D6 T188C variant is associated with lung cancer risk in the Chinese population
verfasst von
Yan Huang
Xin Liu
Xin Kuang
Duanfang Liao
Publikationsdatum
01.08.2013
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 4/2013
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-0755-6

Weitere Artikel der Ausgabe 4/2013

Tumor Biology 4/2013 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.